Prostate CancerAI-MM_CPRCNCT07658573
AI Multimodal Model for Predicting CRPC Progression Risk
An observational study of Prostate Cancer and Castration-Resistant Prostate Cancer, run by Guangxi Medical University at 1 site in China.
Trial summary
This study aims to develop an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing castration-resistant prostate cancer (CRPC), a more severe form of the disease. Read more about this study
- Who is it for?
- Ages 18 to 80 years, men only
- Conditions the study is for
- Prostate Cancer, Castration-Resistant Prostate Cancer
- How many people
- 500 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2025to 1 Jun 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- Men only
- No healthy volunteers
- Adult, Older adult
Study population: Male patients with newly diagnosed advanced prostate cancer
Who may be able to join
- (1) Male, age ≥18 years; (2) Pathologically confirmed newly diagnosed advanced prostate cancer; (3) Received at least 6 months of androgen deprivation therapy OR underwent radical prostatectomy; (4) Have complete baseline MRI (T2WI, DWI, ADC) and biopsy pathology data; (5) Have complete follow-up records (at least 24 months).
Who cannot join
- (1) Missing clinical information; (2) MRI images of poor quality or missing key sequences; (3) Poor quality pathological specimens; (4) Lost to follow-up or incomplete data during follow-up; (5) Concurrent other malignant tumors; (6) Prior anti-tumor therapy.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Artificial Intelligence for Predicting Progression Risk of Castration-Resistant Prostate Cancer by Integrating Multimodal Data: A Multicenter, Retrospective Study
This study aims to develop an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing castration-resistant prostate cancer (CRPC), a more severe form of the disease. The study will use pre-treatment MRI images, biopsy pathology slides, and clinical data collected from patients who received either hormone therapy (ADT) or radical prostatectomy surgery. By integrating these different types of data, the AI model is designed to help doctors identify high-risk patients earlier, personalize treatment plans, and ultimately improve patient outcomes. This is a multicenter, retrospective study that will analyze data from over 500 patients with at least 24 months of follow-up. The performance of the model will be evaluated using standard accuracy metrics.
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| ADT Treatment Group | Patients with newly diagnosed advanced prostate cancer who received at least 6 months of androgen deprivation therapy. | |
| Radical Prostatectomy Group | Patients with localized or locally advanced prostate cancer who underwent radical prostatectomy. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prediction of CRPC Progression Risk in the ADT Treatment Group
Performance of the multimodal AI model in predicting progression to castration-resistant prostate cancer in patients with newly diagnosed advanced prostate cancer who received at least 6 months of androgen deprivation therapy. Metrics include AUC, accuracy, sensitivity, and specificity.
Measured: Minimum 24 months of follow-up
Prediction of CRPC Progression Risk in the Radical Prostatectomy Group
Performance of the multimodal AI model in predicting progression to castration-resistant prostate cancer in patients with newly diagnosed advanced prostate cancer who underwent radical prostatectomy. Metrics include AUC, accuracy, sensitivity, and specificity.
Measured: Minimum 24 months of follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2026
- Study start1 Jun 2025
- Primary completion1 Jun 2028 (estimated)
- Study completion1 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Guangxi Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Fubo Wang, Guangxi Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07658573
- Sponsor's protocol ID
- KY20250243
- Acronym
- AI-MM_CPRC
- Status last verified
- Jun 2026
- First submitted
- 14 Jun 2026
- Last updated
- 22 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Artificial Intelligence for Predicting Progression Risk of Castration-Resistant Prostate Cancer by Integrating Multimodal Data: A Multicenter, Retrospective Study
- ClinicalTrials.gov ID
- NCT07658573
- Acronym / sponsor ID
- AI-MM_CPRC / KY20250243
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Guangxi Medical UniversityUniversity, hospital or other
- Study start
- 1 Jun 2025 (actual)
- Primary completion
- 1 Jun 2028 (estimated)
- Study completion
- 1 Jun 2028 (estimated)
- First posted
- 22 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to develop an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing castration-resistant prostate cancer (CRPC), a more severe form of the disease. The study will use pre-treatment MRI images, biopsy pathology slides, and clinical data collected from patients who received either hormone therapy (ADT) or radical prostatectomy surgery. By integrating these different types of data, the AI model is designed to help doctors identify high-risk patients earlier, personalize treatment plans, and ultimately improve patient outcomes. This is a multicenter, retrospective study that will analyze data from over 500 patients with at least 24 months of follow-up. The performance of the model will be evaluated using standard accuracy metrics.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ADT Treatment Group | – | –Patients with newly diagnosed advanced prostate cancer who received at least 6 months of androgen deprivation therapy. |
| Radical Prostatectomy Group | – | –Patients with localized or locally advanced prostate cancer who underwent radical prostatectomy. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Male patients with newly diagnosed advanced prostate cancer
Key inclusion criteria (1 listed)
- (1) Male, age ≥18 years; (2) Pathologically confirmed newly diagnosed advanced prostate cancer; (3) Received at least 6 months of androgen deprivation therapy OR underwent radical prostatectomy; (4) Have complete baseline MRI (T2WI, DWI, ADC) and biopsy pathology data; (5) Have complete follow-up records (at least 24 months).
Key exclusion criteria (1 listed)
- (1) Missing clinical information; (2) MRI images of poor quality or missing key sequences; (3) Poor quality pathological specimens; (4) Lost to follow-up or incomplete data during follow-up; (5) Concurrent other malignant tumors; (6) Prior anti-tumor therapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prediction of CRPC Progression Risk in the ADT Treatment Group
Time frame: Minimum 24 months of follow-up
Performance of the multimodal AI model in predicting progression to castration-resistant prostate cancer in patients with newly diagnosed advanced prostate cancer who received at least 6 months of androgen deprivation therapy. Metrics include AUC, accuracy, sensitivity, and specificity.
Prediction of CRPC Progression Risk in the Radical Prostatectomy Group
Time frame: Minimum 24 months of follow-up
Performance of the multimodal AI model in predicting progression to castration-resistant prostate cancer in patients with newly diagnosed advanced prostate cancer who underwent radical prostatectomy. Metrics include AUC, accuracy, sensitivity, and specificity.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2026.
Related trials for Prostate Cancer
RecruitingPhase 1/2
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Metastatic Prostate Cancer
RecruitingPhase 1
A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer
Prostatic Neoplasms
RecruitingPhase 3
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant
RecruitingPhase 2
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma
RecruitingPhase 3
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prostate Cancer and Castration-Resistant Prostate Cancer, run by Guangxi Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prediction of CRPC Progression Risk in the ADT Treatment Group (time frame: Minimum 24 months of follow-up). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.